In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients. Επικοινωνία Submitted by Δημήτρης Σπάχος on Πέμ, 04/21/2016 - 11:32
